{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035908","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.845303+00:00","generated_at":"2026-06-04T08:29:32.396285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Stoke Therapeutics reports 2023 net loss $104.7M; cash $201.4M to fund to end 2025","bullets":["Cash, equivalents & marketable securities $201.4M as of Dec 31, 2023; expected to fund operations through end of 2025.","Net loss for FY 2023 was $104.7M ($2.38 per share) vs $101.1M ($2.60 per share) in 2022.","Revenue from Acadia collaboration fell to $8.8M from $12.4M YoY.","R&D expenses $82.2M (2022: $77.8M); G&A $41.3M (2022: $38.9M), driven by STK-001 and STK-002 development.","Q4 2023 net loss $27.0M ($0.60 per share) vs $25.7M ($0.65 per share) in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035908","json":"https://secwatch.observer/filing/0000950170-24-035908.json","markdown":"https://secwatch.observer/filing/0000950170-24-035908.md","text":"https://secwatch.observer/filing/0000950170-24-035908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/0000950170-24-035908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/stok-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:29:32.396285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae7e5118a671bb7c63cb56a3e5b3fc5bfec2e07c","claim":"Stoke Therapeutics, Inc. reported the full year ended December 31, 2023 results: revenue $8.8 million, net income $104.7 million, or $2.38 per share, EPS $2.38 per share.","evidence_excerpt":"Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2023 was $8.8 million, compared to $12.4 million, for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024035908/0000950170-24-035908-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$8.8 million"},{"label":"Net income","value":"$104.7 million, or $2.38 per share"},{"label":"EPS","value":"$2.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}